Physician profile
Christopher Case
NPI 1871552794
$121,088.89
in general payments reported to CMS, 2019-2025
37 companies · $8,590 in 2025
The $8,590 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $12K · 2021: $22K · 2022: $32K · 2023: $8,655 · 2024: $11K · 2025: $8,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $2,790 · Food and Beverage: $1,228 · Travel and Lodging: $207 · Education: $63.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,566.50 |
| Consulting Fee | $2,790.00 |
| Food and Beverage | $1,228.28 |
| Travel and Lodging | $206.50 |
| Education | $63.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98,872.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $15,032.82 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $4,865.59 | 2019-2020 | |
| Corcept Therapeutics | $284.75 | 2020-2025 | Korlym |
| Dexcom, INC. | $280.63 | 2019-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $188.61 | 2019-2025 | Repatha, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $161.53 | 2019-2022 | |
| Abbott Laboratories | $150.73 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $124.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.22 | 2022-2025 | |
| Lilly USA, LLC | $118.89 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $110.17 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $103.36 | 2019-2025 | Tymlos |
| Abbvie INC. | $93.55 | 2020-2022 | |
| Ibsa Pharma INC. | $50.44 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $44.04 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.73 | 2019-2020 | |
| Medtronic Minimed, INC. | $36.92 | 2019-2020 | |
| Tolmar, INC. | $35.26 | 2024-2025 | Jatenzo |
| Horizon Therapeutics Plc | $34.83 | 2021-2023 | Tepezza |
| Antares Pharma, INC. | $31.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.62 | 2019-2020 | |
| Pfizer INC. | $28.66 | 2025 | |
| Insulet Corporation | $28.65 | 2019 | |
| Medtronic, INC. | $26.36 | 2025 | Kyphon Express II Kyphopak Tray |
| Astrazeneca Pharmaceuticals Lp | $25.66 | 2021 | |
| Clarus Therapeutics INC. | $24.60 | 2021 | |
| Averitas Pharma INC. | $21.31 | 2024 | Qutenza |
| Aytu Biopharma, INC. | $20.67 | 2019 | |
| Lifescan, INC. | $17.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.47 | 2019 | |
| Mannkind Corporation | $14.88 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.24 | 2019 | |
| Merck Sharp & Dohme LLC | $12.22 | 2019 | |
| Currax Pharmaceuticals LLC | $11.67 | 2019 | |
| Tandem Diabetes Care, INC. | $11.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.